Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03713346 · ClinicalTrials.gov registry record · NA
Comparing the Digestion of Milk With Different Beta-casein Protein Content by Dairy Intolerant Persons
A NA study of Dairy Intolerance, sponsored by Purdue University.
- Completed
- Registry status
- NA
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT03713346: Completed NA study of Dairy Intolerance, sponsored by Purdue University.
NCT03713346 is a NA study of Dairy Intolerance that has completed, run by Purdue University. The registered enrollment target is 42 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03713346, a NA study of Dairy Intolerance, has completed, sponsored by Purdue University.
- COMPLETED
- Registry status
- NA
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
Persons with dairy intolerance may experience cramps/abdominal pain, bloating, flatulence, acute diarrhea, or fecal urgency when they ingest excessive amounts of lactose. The intensity of these conditions can be mild or severe and likely depends on numerous variables including dose, transit time, intestinal residual lactase activity and microbiome potential to ferment lactose. Jersey cattle produce milk containing high levels of the A2 β-casein protein . There are claims that high A2 β-casein milk is more easily digested by people who are lactose maldigesters . We propose to conduct a double-blinded, randomized, controlled trial to determine if high A2 β-casein milk from Jersey cattle is actually better digested and tolerated by lactose maldigesters.
Primary Outcome
Differences in AUC ΔH2 concentrations (primary outcomes) among milk phases is examined by repeated-measures analysis of variance (ANOVA)
Conditions Studied
Interventions
- OTHER Lactose free milk
- OTHER Jersey milk
- OTHER High A1 β-casein milk
- OTHER High A2 β-casein milk
Study Locations (1)
Indiana
- Purdue University - West Lafayette
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2018-01-17 |
| Est. Completion | 2021-09-03 |
| Phase | NA |
What the finished NCT03713346 record still lists
NCT03713346 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Dairy Intolerance appearing as the primary indexed condition, and to 4 interventions - of which Lactose free milk is the first listed.
NCT03713346 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT03713346 about?
NCT03713346 is a clinical study titled "Comparing the Digestion of Milk With Different Beta-casein Protein Content by Dairy Intolerant Persons". Persons with dairy intolerance may experience cramps/abdominal pain, bloating, flatulence, acute diarrhea, or fecal urgency when they ingest excessive amounts of lactose. The intensity of these conditions can be mild or severe and likely depends on numerous variables including dose, transit time, in...
What is the current status of trial NCT03713346?
This trial is currently completed. It is a NA study. The enrollment target is 42 participants. The study started on 2018-01-17. Estimated completion is 2021-09-03.
What conditions does trial NCT03713346 study?
This clinical trial studies the following conditions: Dairy Intolerance.
What interventions are being tested in trial NCT03713346?
The interventions under investigation include: Lactose free milk (OTHER), Jersey milk (OTHER), High A1 β-casein milk (OTHER), High A2 β-casein milk (OTHER).
Who is sponsoring clinical trial NCT03713346?
This trial is sponsored by Purdue University, which has 141 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03713346 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03713346's enrollment target sits among peer trials
42 1436th of 2000 higher than 555 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI